Celyad Oncology SA (CLYYF)

0.3580 0.0000 (0.00%) At close: 09:30AM EDT

Celyad Oncology SA

Axis Business Park
Rue André Dumont 9
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
https://www.celyad.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME	Co-Founder, Interim CEO & Executive Director	100.9k	N/A	1956
Mr. David Georges	Vice President of Finance & Administration	N/A	N/A	1976
Sara Zelkovic	Communications & Investor Relations Director	N/A	N/A	N/A
Ms. An Phan	Head of Legal	N/A	N/A	1975
Mr. Hannes Iserentant	Head of Intellectual Property	N/A	N/A	1978
Mr. Eytan Breman	Head of R&D	N/A	N/A	1980
Mr. Philippe Dechamps	Corporate Secretary	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; Multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery / PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate governance

Celyad Oncology SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.